Re: Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study.
作者信息
Spaas Mathieu, Sundahl Nora, Ost Piet
机构信息
Department of Radiation Oncology and Experimental Cancer Research, Ghent University Hospital, Ghent, Belgium; Cancer Research Institute Ghent, Ghent University, Ghent, Belgium.
Department of Radiation Oncology and Experimental Cancer Research, Ghent University Hospital, Ghent, Belgium; Cancer Research Institute Ghent, Ghent University, Ghent, Belgium.
出版信息
Eur Urol. 2022 Feb;81(2):216. doi: 10.1016/j.eururo.2021.11.003. Epub 2021 Nov 20.
PMID:34810013
Abstract
摘要
相似文献
1
Re: Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study.回复：纳武利尤单抗联合立体定向体部放疗用于经治转移性肾细胞癌患者。II期NIVES研究结果
Eur Urol. 2022 Feb;81(2):216. doi: 10.1016/j.eururo.2021.11.003. Epub 2021 Nov 20.
2
Re: Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study.回复：纳武利尤单抗联合立体定向体部放疗用于经治转移性肾细胞癌患者。II期NIVES研究结果
Eur Urol. 2022 Jun;81(6):622. doi: 10.1016/j.eururo.2022.02.017. Epub 2022 Mar 10.
3
Re: Cristina Masini, Cinzia Iotti, Ugo De Giorgi, et al. Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. Eur Urol. 2022;81:274-82.回复：克里斯蒂娜·马西尼、钦齐亚·约蒂、乌戈·德·乔治等。纳武单抗联合立体定向体部放疗用于转移性肾细胞癌经治患者。II期NIVES研究结果。《欧洲泌尿外科杂志》。2022年；81卷：274 - 82页。
Eur Urol. 2022 Apr;81(4):e98-e99. doi: 10.1016/j.eururo.2021.11.034. Epub 2022 Jan 4.
4
Re: Cristina Masini, Cinzia Iotti, Ugo De Giorgi, et al. Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. Eur Urol. 2022;81:274-82.回复：克里斯蒂娜·马西尼、钦齐亚·约蒂、乌戈·德·乔治等。纳武利尤单抗联合立体定向体部放疗用于经治转移性肾细胞癌患者。II期NIVES研究结果。《欧洲泌尿外科杂志》。2022年；81卷：274 - 82页。
Eur Urol. 2022 Apr;81(4):e96-e97. doi: 10.1016/j.eururo.2021.11.035. Epub 2022 Jan 3.
5
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study.纳武利尤单抗联合立体定向放疗治疗预处理转移性肾细胞癌患者：Ⅱ期 NIVES 研究结果。
Eur Urol. 2022 Mar;81(3):274-282. doi: 10.1016/j.eururo.2021.09.016. Epub 2021 Oct 1.
6
C-reactive protein can be used to predict the therapeutic effects of nivolumab in patients with metastatic renal cell carcinoma.C反应蛋白可用于预测纳武单抗对转移性肾细胞癌患者的治疗效果。
Int J Urol. 2019 Nov;26(11):1076-1077. doi: 10.1111/iju.14084. Epub 2019 Jul 31.
7
Exceptional Response to Nivolumab Rechallenge in Metastatic Renal Cell Carcinoma with Parallel Changes in Genomic Profile.纳武单抗再激发治疗转移性肾细胞癌的卓越反应及基因组图谱的平行变化
Eur Urol. 2018 Feb;73(2):308-310. doi: 10.1016/j.eururo.2017.08.006. Epub 2017 Aug 24.
8
Efficacy and Toxicity of Fifth-line Nivolumab in a 15-Year-Old Girl With Metastatic Juvenile Renal Cell Carcinoma.纳武单抗用于一名15岁转移性青少年肾细胞癌女孩的五线治疗的疗效与毒性
J Pediatr Hematol Oncol. 2018 Apr;40(3):251-252. doi: 10.1097/MPH.0000000000001086.
9
10
Case of complete response to neoadjuvant therapy using nivolumab in a patient with metastatic renal cell carcinoma.一例转移性肾细胞癌患者使用纳武单抗新辅助治疗后完全缓解的病例。
Int J Urol. 2018 Jun;25(6):630-632. doi: 10.1111/iju.13590. Epub 2018 Apr 25.
引用本文的文献
1
Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer.转移性激素敏感前列腺癌系统治疗的未来方向。
World J Urol. 2023 Aug;41(8):2021-2031. doi: 10.1007/s00345-022-04135-8. Epub 2022 Aug 27.
Zotero 插件